The ADAPT phase 3 trial evaluated efgartigimod, an engineered Fc-fragment that blocks the neonatal Fc receptor and reduces circulating pathogenic IgG. Adults with generalized myasthenia gravis received efgartigimod or placebo in repeated treatment cycles. Among acetylcholine-receptor antibody-positive participants, a substantially larger proportion achieved the prespecified MG-ADL responder outcome with efgartigimod during the first cycle. The treatment was generally well tolerated, with headache and nasopharyngitis among the more common adverse events. The study is important because it demonstrated that modulating IgG recycling can translate into rapid clinical improvement in a broad MG population. For HCPs, efgartigimod provides a targeted treatment option for patients whose generalized symptoms remain burdensome despite background therapy. Clinical response should guide the interval between treatment cycles rather than assuming a fixed schedule for every patient. The trial also reinforces the value of measuring patient-centred outcomes such as activities of daily living in addition to muscle strength. The findings directly complement IANCON's focus on practical pharmacotherapy and advanced treatment options for myasthenia gravis.